Oral Cyclophosphamide for Patients With Metastatic Castration-Resistant Prostate Cancer in a Scenario of Limited Health Care Resources

PURPOSEPrior noncontemporary studies showed that oral cyclophosphamide is an active treatment of metastatic castration-resistant prostate cancer (mCRPC). However, cyclophosphamide is currently underutilized in routine clinical practice given the lack of survival benefit and the emergence of more eff...

Descrición completa

Detalles Bibliográficos

Principais autores:	Diana del Cisne Pineda, Gabriel Berlingieri Polho, Yumi Ricucci Shinkado, Gustavo Alves Contado, Nathalia de Souza Crusoe, Vivian Naomi Horita, Joao Carlos Resende, Jamile Almeida Silva, Guilherme Fialho de Freitas, David Queiroz Muniz, Caio V. Suartz, Leopoldo Alves Ribeiro-Filho, Paulo M. Hoff, José Mauricio Mota
Formato:	Artigo
Idioma:	Inglês
Publicado:	American Society of Clinical Oncology 2025-04-01
Series:	JCO Global Oncology
Acceso en liña:	https://ascopubs.org/doi/10.1200/GO-24-00464
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!